NCT02585973 is a Phase 1 clinical trial of AZD1775 in Carcinoma, Squamous Cell of Head and Neck, sponsored by UNC Lineberger Comprehensive Cancer Center.

Who is sponsoring NCT02585973?

NCT02585973 is sponsored by UNC Lineberger Comprehensive Cancer Center.

What drugs are being tested in NCT02585973?

Interventions in NCT02585973: AZD1775, Cisplatin, Intensity Modulated Radiotherapy Treatments.

What condition does NCT02585973 study?

NCT02585973 studies Carcinoma, Squamous Cell of Head and Neck.

Is NCT02585973 still recruiting?

NCT02585973 is currently completed. Last updated 29 June 2021.

Last reviewed 2021-06-29 · How we verify

NCT02585973

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Completed Phase 1 Last updated 29 June 2021

What this trial tests

Phase 1 trial testing AZD1775 in Carcinoma, Squamous Cell of Head and Neck in 12 participants. Completed in 23 June 2021.

Timeline

26 October 2015

Primary endpoint
14 June 2019

23 June 2021

Quick facts

Lead sponsor	UNC Lineberger Comprehensive Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	26 October 2015
Primary completion	14 June 2019
Estimated completion	23 June 2021
Sites	1 location across United States

Drugs / interventions tested

AZD1775 — full drug profile →
Cisplatin (cisplatin) — full drug profile →
Intensity Modulated Radiotherapy Treatments

Conditions studied

Carcinoma, Squamous Cell of Head and Neck — all drugs for Carcinoma, Squamous Cell of Head and Neck →

Sponsor

UNC Lineberger Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Squamous Cell of Head and Neck. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy (cisplatin) and radiation for the treatment of locally advanced squamous cell cancer of the head and neck (HNSCC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

State-of-the-art strategies for targeting the DNA damage response in cancer.
Pilié PG, Tang C, Mills GB, Yap TA. · · 2019 · cited 876× · PMID 30356138 · DOI 10.1038/s41571-018-0114-z
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
Ghelli Luserna di Rorà A, Cerchione C, Martinelli G, Simonetti G. · · 2020 · cited 232× · PMID 32958072 · DOI 10.1186/s13045-020-00959-2
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.
Petroni G, Cantley LC, Santambrogio L, Formenti SC, et al · · 2022 · cited 154× · PMID 34819622 · DOI 10.1038/s41571-021-00579-w
Targeting the DNA Damage Response in OSCC with TP53 Mutations.
Lindemann A, Takahashi H, Patel AA, Osman AA, et al · · 2018 · cited 117× · PMID 29489434 · DOI 10.1177/0022034518759068
Leveraging the replication stress response to optimize cancer therapy.
Cybulla E, Vindigni A. · · 2023 · cited 109× · PMID 36323800 · DOI 10.1038/s41568-022-00518-6
Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting.
Biau J, Chautard E, Verrelle P, Dutreix M. · · 2019 · cited 91× · PMID 31649878 · DOI 10.3389/fonc.2019.01009
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP, Li L, Aparicio AM, Corn PG, et al · · 2017 · cited 91× · PMID 27978798 · DOI 10.2174/0929867323666161214114948
Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1.
Bukhari AB, Chan GK, Gamper AM. · · 2022 · cited 50× · PMID 35251998 · DOI 10.3389/fonc.2022.828684

Verify or expand the search:

Other trials of AZD1775

Trials testing the same drug.

NCT03668340 — AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma · Phase 2 · active not recruiting
NCT03028766 — WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer · Phase 1 · completed
NCT03012477 — CISPLATIN + AZD-1775 In Breast Cancer · Phase 2 · completed
NCT02546661 — Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer · Phase 1 · active not recruiting
NCT02688907 — Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplificat · Phase 2 · terminated

Other recruiting trials for Carcinoma, Squamous Cell of Head and Neck

Currently open trials in the same condition.

NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
NCT03485209 — Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors · Phase 2 · active not recruiting

Other UNC Lineberger Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06656936 — The PharmFIT Study · NA · not yet recruiting
NCT05937659 — Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT · not yet recruiting
NCT07479199 — Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors · not yet recruiting
NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · Phase 2 · recruiting
NCT04266730 — Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02585973 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center
Last refreshed: 29 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02585973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing